Ocular Therapeutix Inc. (NASDAQ:OCUL) finished Wednesday with a subtraction of -$0.53 to close at $11.54, a downside of -4.39 percent. An average of 2,188,200 shares of common stock have been traded in the last five days. There was a gain of $1.64 in the past week. The last 20 days have seen an average of 1,103,430 shares traded, while the 50-day average volume stands at 892,858.
OCUL stock has increased by 7.85% in the last month. The company shares reached their 1-month lowest point of $9.45 on 10/06/21. With the stock rallying to its 52-week high on 01/11/21, shares of the company touched a low of $9.11 and a high of $24.30 in 52 weeks. In spite of this, the price is down -52.51% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
147 days have passed since Ocular Therapeutix Inc. (OCUL) last reported insider trading activity. LINDSTROM RICHARD L MD, who is Director, most recently acquired $10,000 shares at $14.30 per share on May 20.
Ocular Therapeutix Inc. (OCUL) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 2.06. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 28.12, the price-to-book (PB) ratio at 10.99.
The quick ratio of Ocular Therapeutix Inc. for the three months ended June 29 was 10.00, and the current ratio was 10.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.63 and a total debt to equity ratio of 0.63 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 90.30% against a 5-year average of 72.5%. Ocular Therapeutix Inc.’s EBITDA margin for the year ending June 29 is -345.19%. Its gross profit as reported stood at $15.32 million compared to revenue of $17.4 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Ocular Therapeutix Inc.’s return on assets was -49.40%, compared to -88.8% over the last five years. In the past year, the return on investment has been -50.00%, and the 5-year average is -115.0%. Meanwhile, the return on equity (ROE) for the past 12 months has been -174.70% and the 5-year average holds at -276.8%. For the broader industry, ROE averaged -68.79 over the past year.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $11.72 million in the quarter, while revenues of $7.34 million were grew 86.6%. The analyst consensus anticipated Ocular Therapeutix Inc.’s latest quarter earnings to come in at -$0.21 per share, but it turned out to be -$0.11, a 47.60% surprise. For the quarter, EBITDA amounted to -$19.62 million. Shareholders own equity worth $76.58 million.
From a technical analysis perspective, let’s take a brief look at Ocular Therapeutix Inc. (OCUL) price momentum. RSI 9-day as of the close on 13 October was 62.57%, suggesting the stock is Neutral, with historical volatility in this time frame at 92.22%.
As of today, OCUL’s price is $10.93 +16.57% or $1.64 from its 5-day moving average. OCUL is currently trading +12.04% higher than its 20-day SMA and -16.07% lower than its 100-day SMA. However, the stock’s current price level is +7.05% above the SMA50 and -43.40% below the SMA200.
The stochastic %K and %D were 76.82% and 59.91%, respectively, and the average true range (ATR) was 0.75. With the 14-day stochastic at 68.52% and the average true range at 0.68, the RSI (14) stands at 58.92%. The stock has reached 1.13 on the 9-day MACD Oscillator while the 14-day reading was at 1.16.
H.C. Wainwright upgraded Ocular Therapeutix Inc. (NASDAQ: OCUL) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Ocular Therapeutix Inc. (OCUL) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell OCUL, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is OCUL’s price target for the next 12 months?
Analysts predict a range of price targets between $15.00 and $34.00, with a median target of $25.00. Taking a look at these predictions, the average price target given by analysts for Ocular Therapeutix Inc. (OCUL) stock is $23.71.